Immunologic Research

, Volume 47, Issue 1–3, pp 56–64 | Cite as

Conformational heterogeneity of MHC class II induced upon binding to different peptides is a key regulator in antigen presentation and epitope selection

  • Scheherazade Sadegh-Nasseri
  • Sateesh Natarajan
  • Chih-Ling Chou
  • Isamu Z. Hartman
  • Kedar Narayan
  • AeRyon Kim
Article

Abstract

T cells bearing αβ receptors recognize antigenic peptides bound to class I and class II glycoproteins encoded in the major histocompatibility complex (MHC). Cytotoxic and helper T cells respond respectively to peptide antigens derived from endogenous sources presented by MHC class I, and exogenous sources presented by MHC II, on antigen presenting cells. Differences in the MHC class I and class II structures and their maturation pathways have evolved to optimize antigen presentation to their respective T cells. A main focus of our laboratory is on efforts to understand molecular events in processing of antigen for presentation by MHC class II. The different stages of MHC class II—interactions with molecular chaperons involved in folding and traffic from the ER through the antigen-loading compartments, peptide exchange, and transport to the cell surface have been investigated. Through intense research on biophysical and biochemical properties of MHC class II molecules, we have learned that the conformational heterogeneity of MHC class II induced upon binding to different peptides is a key regulator in antigen presentation and epitope selection, and a determinant of the ability of MHC class II to participate in peptide association or dissociation and interaction with the peptide editor HLA-DM.

Keywords

MHC class II Kinetics Conformational heterogeneity Immunodominance H-bonds Peptide-receptive conformation 

References

  1. 1.
    Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol. 1993;11:403–50.CrossRefPubMedGoogle Scholar
  2. 2.
    Sadegh-Nasseri S, Germain RN. How MHC class II molecules work: peptide-dependent completion of protein folding. Immunol Today. 1992;13(2):43–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Sadegh-Nasseri S, Germain RN. A role for peptide in determining MHC class II structure. Nature. 1991;353(6340):167–70.CrossRefPubMedGoogle Scholar
  4. 4.
    Sadegh-Nasseri S, McConnell HM. A kinetic intermediate in the reaction of an antigenic peptide and I-Ek. Nature. 1989;337(6204):274–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Sadegh-Nasseri S, Stern LJ, Wiley DC, Germain RN. MHC class II function preserved by low-affinity peptide interactions preceding stable binding. Nature. 1994;370(6491):647–50.CrossRefPubMedGoogle Scholar
  6. 6.
    Sato AK, Zarutskie JA, Rushe MM, Lomakin A, Natarajan SK, Sadegh-Nasseri S, et al. Determinants of the peptide-induced conformational change in the human class II major histocompatibility complex protein HLA-DR1. J Biol Chem. 2000;275(3):2165–73.CrossRefPubMedGoogle Scholar
  7. 7.
    Carven GJ, Stern LJ. Probing the ligand-induced conformational change in HLA-DR1 by selective chemical modification and mass spectrometric mapping. Biochemistry. 2005;44(42):13625–37.CrossRefPubMedGoogle Scholar
  8. 8.
    Dornmair K, Rothenhausler B, McConnell HM. Structural intermediates in the reactions of antigenic peptides with MHC molecules. Cold Spring Harb Symp Quant Biol. 1989;54(Pt 1):409–16.PubMedGoogle Scholar
  9. 9.
    Witt SN, McConnell HM. Formation and dissociation of short-lived class II MHC-peptide complexes. Biochemistry. 1994;33(7):1861–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Schmitt L, Boniface JJ, Davis MM, McConnell HM. Conformational isomers of a class II MHC-peptide complex in solution. J Mol Biol. 1999;286(1):207–18.CrossRefPubMedGoogle Scholar
  11. 11.
    Natarajan SK, Assadi M, Sadegh-Nasseri S. Stable peptide binding to MHC class II molecule is rapid and is determined by a receptive conformation shaped by prior association with low affinity peptides. J Immunol. 1999;162(7):4030–6.PubMedGoogle Scholar
  12. 12.
    Rabinowitz JD, Vrljic M, Kasson PM, Liang MN, Busch R, Boniface JJ, et al. Formation of a highly peptide-receptive state of class II MHC. Immunity. 1998;9(5):699–709.CrossRefPubMedGoogle Scholar
  13. 13.
    Zarutskie JA, Busch R, Zavala-Ruiz Z, Rushe M, Mellins ED, Stern LJ. The kinetic basis of peptide exchange catalysis by HLA-dm. Proc Natl Acad Sci USA. 2001;98(22):12450–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Watts TH, Brian AA, Kappler JW, Marrack P, McConnell HM. Antigen presentation by supported planar membranes containing affinity-purified I-Ad. Proc Natl Acad Sci USA. 1984;81(23):7564–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Buus S, Sette A, Colon SM, Jenis DM, Grey HM. Isolation and characterization of antigen-IA complexes involved in T cell recognition. Cell. 1986;47(6):1071–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Dornmair K, McConnell HM. Refolding and reassembly of separate alpha and beta chains of class II molecules of the major histocompatibility complex leads to increased peptide-binding capacity. Proc Natl Acad Sci USA. 1990;87(11):4134–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Germain RN, Hendrix LR. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. Nature. 1991;353(6340):134–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Davidson HW, Reid PA, Lanzavecchia A, Watts C. Processed antigen binds to newly synthesized MHC class II molecules in antigen-specific b lymphocytes. Cell. 1991;67(1):105–16.CrossRefPubMedGoogle Scholar
  19. 19.
    Sadegh-Nasseri S. Peptide, invariant chain, or molecular aggregation preserves class II from functional inactivation. In: Humphreys RE, Pierce SK, editors. Antigen processing and presentation, vol. 1. San Diego: Academic Press; 1994. p. 170–87.Google Scholar
  20. 20.
    Park SJ, Sadegh-Nasseri S, Wiley DC. Invariant chain made in Escherichia coli has an exposed n-terminal segment that blocks antigen binding to HLA-DR1 and a trimeric c-terminal segment that binds empty HLA-DR1. Proc Natl Acad Sci USA. 1995;92(24):11289–93.CrossRefPubMedGoogle Scholar
  21. 21.
    Jardetzky TS, Gorga JC, Busch R, Rothbard J, Strominger JL, Wiley DC. Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding. EMBO J. 1990;9(6):1797–803.PubMedGoogle Scholar
  22. 22.
    Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature. 1994;368(6468):215–21.CrossRefPubMedGoogle Scholar
  23. 23.
    Murthy VL, Stern LJ. The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide binding. Structure. 1997;5(10):1385–96.CrossRefPubMedGoogle Scholar
  24. 24.
    Hammer J, Valsasnini P, Tolba K, Bolin D, Higelin J, Takacs B, et al. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell. 1993;74(1):197–203.CrossRefPubMedGoogle Scholar
  25. 25.
    Wu S, Gorski J, Eckels DD, Newton-Nash DK. T cell recognition of MHC class II-associated peptides is independent of peptide affinity for MHC and sodium dodecyl sulfate stability of the peptide/MHC complex. Effects of conservative amino acid substitutions at anchor position 1 of influenza matrix protein19–31. J Immunol. 1996;156(10):3815–20.PubMedGoogle Scholar
  26. 26.
    Verreck FA, Vermeulen C, Poel AV, Jorritsma P, Amons R, Coligan JE, et al. The generation of SDS-stable HLA DR dimers is independent of efficient peptide binding. Int Immunol. 1996;8(3):397–404.CrossRefPubMedGoogle Scholar
  27. 27.
    Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DA, et al. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature. 1992;358(6389):764–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Natarajan SK, Stern LJ, Sadegh-Nasseri S. Sodium dodecyl sulfate stability of HLA-DR1 complexes correlates with burial of hydrophobic residues in pocket 1. J Immunol. 1999;162(6):3463–70.PubMedGoogle Scholar
  29. 29.
    Stern LJ, Wiley DC. The human class II MHC protein HLA-DR1 assembles as empty alpha beta heterodimers in the absence of antigenic peptide. Cell. 1992;68(3):465–77.CrossRefPubMedGoogle Scholar
  30. 30.
    Germain RN, Rinker AG Jr. Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules. Nature. 1993;363(6431):725–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Romagnoli P, Germain RN. The clip region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. J Exp Med. 1994;180(3):1107–13.CrossRefPubMedGoogle Scholar
  32. 32.
    Chou CL, Sadegh-Nasseri S. HLA-dm recognizes the flexible conformation of major histocompatibility complex class II. J Exp Med. 2000;192(12):1697–706.CrossRefPubMedGoogle Scholar
  33. 33.
    Pu Z, Lovitch SB, Bikoff EK, Unanue ER. T cells distinguish MHC-peptide complexes formed in separate vesicles and edited by H2-DM. Immunity. 2004;20(4):467–76.CrossRefPubMedGoogle Scholar
  34. 34.
    Marin-Esteban V, Falk K, Rotzschke O. “Chemical analogues” Of HLA-DM can induce a peptide-receptive state in HLA-DR molecules. J Biol Chem. 2004;279(49):50684–90.CrossRefPubMedGoogle Scholar
  35. 35.
    Pashine A, Busch R, Belmares MP, Munning JN, Doebele RC, Buckingham M, et al. Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. Immunity. 2003;19(2):183–92.CrossRefPubMedGoogle Scholar
  36. 36.
    Belmares MP, Busch R, Mellins ED, McConnell HM. Formation of two peptide/MHC II isomers is catalyzed differentially by HLA-DM. Biochemistry. 2003;42(3):838–47.CrossRefPubMedGoogle Scholar
  37. 37.
    Stratikos E, Mosyak L, Zaller DM, Wiley DC. Identification of the lateral interaction surfaces of human histocompatibility leukocyte antigen (HLA)-DM with HLA-DR1 by formation of tethered complexes that present enhanced HLA-dm catalysis. J Exp Med. 2002;196(2):173–83.CrossRefPubMedGoogle Scholar
  38. 38.
    Doebele RC, Busch R, Scott HM, Pashine A, Mellins ED. Determination of the HLA-DM interaction site on HLA-DR molecules. Immunity. 2000;13(4):517–27.CrossRefPubMedGoogle Scholar
  39. 39.
    Narayan K, Chou CL, Kim A, Hartman IZ, Dalai S, Khoruzhenko S, et al. HLA-DM targets the hydrogen bond between the histidine at position beta81 and peptide to dissociate HLA-DR-peptide complexes. Nat Immunol. 2007;8(1):92–100.CrossRefPubMedGoogle Scholar
  40. 40.
    Fremont DH, HenDRickson WA, Marrack P, Kappler J. Structures of an MHC class II molecule with covalently bound single peptides. Science. 1996;272(5264):1001–4.CrossRefPubMedGoogle Scholar
  41. 41.
    Fremont DH, Monnaie D, Nelson CA, HenDRickson WA, Unanue ER. Crystal structure of I-Ak in complex with a dominant epitope of lysozyme. Immunity. 1998;8(3):305–17.CrossRefPubMedGoogle Scholar
  42. 42.
    Wilson N, Fremont D, Marrack P, Kappler J. Mutations changing the kinetics of class II MHC peptide exchange. Immunity. 2001;14(5):513–22.CrossRefPubMedGoogle Scholar
  43. 43.
    McFarland BJ, Beeson C, Sant AJ. Cutting edge: a single, essential hydrogen bond controls the stability of peptide-MHC class II complexes. J Immunol. 1999;163(7):3567–71.PubMedGoogle Scholar
  44. 44.
    Saito K, Oda M, Sarai A, Azuma T, Kozono H. Contribution of a single hydrogen bond between betahis81 of MHC class II I-E(k) and the bound peptide to the PH-dependent thermal stability. Microbiol Immunol. 2004;48(1):53–7.PubMedGoogle Scholar
  45. 45.
    Sadegh-Nasseri S, Chen M, Narayan K, Bouvier M. The convergent roles of tapasin and HLA-DM in antigen presentation. Trends Immunol. 2008;29(3):141–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Narayan K, Su KW, Chou CL, Khoruzhenko S, Sadegh-Nasseri S. HLA-DM mediates peptide exchange by interacting transiently and repeatedly with HLA-DR1. Mol Immunol. 2009;46(15):3157–62.CrossRefPubMedGoogle Scholar
  47. 47.
    Chen M, Bouvier M. Analysis of interactions in a tapasin/class I complex provides a mechanism for peptide selection. EMBO J. 2007;26(6):1681–90.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Scheherazade Sadegh-Nasseri
    • 1
  • Sateesh Natarajan
    • 2
    • 1
  • Chih-Ling Chou
    • 3
    • 1
  • Isamu Z. Hartman
    • 4
    • 1
  • Kedar Narayan
    • 5
    • 1
  • AeRyon Kim
    • 1
  1. 1.Department of PathologyJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.DendreonSeattleUSA
  3. 3.Program in NeuroscienceThe University of Arizona, College of PharmacyTucsonUSA
  4. 4.Department of Molecular GeneticsUniversity of Texas Southwestern Medical CenterDallasUSA
  5. 5.Laboratory of Cell BiologyNCI, NIHBethesdaUSA

Personalised recommendations